Oxford Asset Management’s Theravance Biopharma TBPH Stock Holding History

Oxford Asset Management’s Portfolio TBPH Stock Details TBPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-14,429	Closed	-$159K	–	732
2025 Q2	$159K	Buy	+14,429	New	+$140K	0.05%	446
2020 Q1	–	Sell	-13,961	Closed	-$361K	–	1192
2019 Q4	$361K	Sell	13,961 -1,148	-8%	-$22.3K	0.01%	1372
2019 Q3	$294K	Buy	+15,109	New	+$305K	0.01%	1466
2015 Q1	–	Sell	-172,016	Closed	-$2.62M	–	734
2014 Q4	$2.62M	Sell	172,016 -152,321	-47%	-$2.65M	0.06%	325
2014 Q3	$7.59M	Buy	324,337 +77,025	+31%	+$2.23M	0.17%	118
2014 Q2	$8.46M	Buy	+247,312	New	+$7.45M	0.27%	98

Other funds holding TBPH

MAP

Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return

WAM

Weiss Asset Management Boston, Massachusetts $5.91B AUM 42.42% 1-Year Est. Return

Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ICM

Irenic Capital Management New York $1.54B AUM 12.79% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PWAM

Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

OMC

Oasis Management Company Grand Cayman, Cayman Islands $1.72B AUM 32.1% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Oxford Asset Management's TBPH Position: Q3 2025 in Review

Oxford Asset Management sold out of Theravance Biopharma (TBPH) in Q3 2025, closing a stake of 14,429 shares — an estimated $159K sold.

Oxford Asset Management first reported a position in TBPH in Q2 2014 and held it in 6 quarters. The position peaked at $8.46M in Q2 2014. 162 funds tracked by Wall St. Rank hold TBPH as of Q3 2025.

Oxford Asset Management reported no remaining Theravance Biopharma position as of Q3 2025 after selling out during the quarter.
Oxford Asset Management sold 14,429 Theravance Biopharma shares in Q3 2025, an estimated $159K.
Oxford Asset Management first reported a position in Theravance Biopharma in Q2 2014 and held it in 6 quarters.
Oxford Asset Management's Theravance Biopharma position peaked at $8.46M in Q2 2014.
162 funds tracked by Wall St. Rank held Theravance Biopharma as of Q3 2025.

Based on Oxford Asset Management's 13F filing for Q3 2025, filed 14 Nov 2025.